...
首页> 外文期刊>Drug metabolism and pharmacokinetics. >Construction of an expression system for human alpha(1)-acid glycoprotein in E. coli: The roles of oligosaccharide moieties in structural and functional properties.
【24h】

Construction of an expression system for human alpha(1)-acid glycoprotein in E. coli: The roles of oligosaccharide moieties in structural and functional properties.

机译:人大肠杆菌中的人α(1)-酸性糖蛋白表达系统的构建:寡糖部分在结构和功能特性中的作用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Unglycosylated recombinant human alpha(1)-acid glycoprotein (hAGP) variants (rF1(*)S and rA) were prepared in an E. coli expression system using the Origami B strain and pET-3c vector. Thioredoxin was co-expressed to promote the appropriate folding of hAGP. SDS-PAGE under reducing conditions showed that rF1(*)S and rA migrate as single bands after purification. However, several bands derived from rA were observed under non-reducing conditions because of the high reactivity of a free cystein residue (C149). We therefore prepared a mutant of A variant (C149R-A), and confirmed that this mutant maintained homogeneity. Circular dichroism and intrinsic tryptophan fluorescence spectroscopic analyses indicated that rF1(*)S and C149R-A have almost the same conformational structures as F1(*)S and A purified from serum. Ligand binding experiments using propranolol as a F1(*)S ligand and disopyramide as an A specific ligand indicated that the capacity of rF1(*)S and C149R-A is equivalent to those ligands as well as F1(*)S and A from serum. These results suggest that the oligosaccharide moieties of hAGP have negligible effects on the structural and ligand binding properties of hAGP. Thus, rF1(*)S and C149R-A promise to be useful in studies on the drug binding sites of hAGP.
机译:使用Origami B菌株和pET-3c载体在大肠杆菌表达系统中制备未糖基化的重组人α(1)-酸性糖蛋白(hAGP)变体(rF1(*)S和rA)。共表达硫氧还蛋白以促进hAGP的适当折叠。 SDS-PAGE在还原条件下显示纯化后rF1(*)S和rA迁移为单条带。但是,由于游离半胱氨酸残基(C149)的高反应性,在非还原条件下观察到了一些源自rA的条带。因此,我们制备了A变体的突变体(C149R-A),并证实了该突变体保持了同质性。圆二色性和固有色氨酸荧光光谱分析表明,rF1(*)S和C149R-A具有与从血清中纯化的F1(*)S和A几乎相同的构象结构。使用普萘洛尔作为F1(*)S配体和双吡amide酰胺作为A特异性配体的配体结合实验表明rF1(*)S和C149R-A的容量与那些配体以及F1(*)S和A的等效血清。这些结果表明,hAGP的寡糖部分对hAGP的结构和配体结合性质的影响可忽略不计。因此,rF1(*)S和C149R-A有望用于hAGP药物结合位点的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号